期刊文献+

甲状腺髓样癌的临床病理特征及治疗 被引量:2

Clinicopathologic characteristics and treatment of medullary thyroid carcinoma
原文传递
导出
摘要 目的总结甲状腺髓样癌(medullary thyroid carcinoma,MTC)的临床病理特征及治疗方法。方法回顾性分析1995年1月至2010年2月福建医科大学省立临床医学院手术治疗的42例MTC临床资料。结果42例均手术治疗,经病理证实为MTC,颈部淋巴结经病理证实转移率为76.19%(32/42),中央区淋巴结转移率为61.90%(26/42)。术后中位随访时间102(1—502)个月,随访5年以上35例(83.33%),5年生存率为85.71%(30/35),死亡5例。结论MTC淋巴结转移率高,治疗应以根治性切除为原则,原发灶处理宜行甲状腺全切除,淋巴结清扫应力求彻底,至少行中央区淋巴结清扫。 Objective To explore the clinicopathologic characteristics and treatment of medullary thyroid carcinoma( MTC ). Methods The data of 42 cases of MTC admitted to Fujian Medical University Provincial Clinical College from Jan 1995 to Feb 2010 were retrospectively analyzed. Surgery was performed in all the 42 cases. All were proved to be MTC by pathology. Results Surgery was performed in all the 42 cases. All were proved to be MTC by pathology. The lymph node metastasis rate was 76. 19% (32/42). The central lymph node metastasis rate was 61.90% (26/42). All the 42 cases were followed up for 1 to 502 months with 102 months as the median. 35 cases(83.33% )were followed up for more than 5 years and the 5-year overall survival rate was 85.71% (30/35). Death occurred in 5 cases. Conclusions The lymph node metastasis rate of MTC is high. The treatment should be based on the principle of radical resection. Total thyroidectomy should be recommended to treat primary tumor. Lymph node dissection should be as thorough as possible. Central compartment neck dis- section should be done in all cases.
出处 《中华内分泌外科杂志》 CAS 2013年第4期275-277,共3页 Chinese Journal of Endocrine Surgery
关键词 甲状腺肿瘤 髓样癌 Thyroid neoplasms Medullary carcinoma
  • 相关文献

参考文献3

二级参考文献27

  • 1吴毅.甲状腺髓样癌的外科治疗[J].中国普外基础与临床杂志,2006,13(3):250-251. 被引量:3
  • 2高再荣,安锐,张永学,Hans J.Biersack.核素靶向治疗在转移性甲状腺髓样癌治疗中的价值[J].中华肿瘤杂志,2006,28(8):621-624. 被引量:8
  • 3Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems [ J ]. Cancer, 2000,88 (5) : 1139-1148.
  • 4Moley .IF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma : recommendations for extent of node dissection[ J ]. Ann Surg, 1999,229 (6) : 880-887.
  • 5Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American thyroid Association [ J]. Thyroid ,2009,19 (6) :565-.612.
  • 6Kebebew E, Ituarte PHG, Siperstein AE, et al. MeduUary thyroid carcinoma : clinical characteristics, treatment, prognostic factors and a comparison of staging systems [ J ]. Cancer,2000,88 (5) : 1139.
  • 7Rohmer V, Vidal-Trecan G, Bourdelot A, et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais dEtude des Tumeurs Endocrines [ J]. J Clin Endocrinol Metab, 2011 ,96(3) :E509-518.
  • 8Dequanter D, Lothaire P. Medullary thyroid cancer: surgical results and prognostic factors[J]. Rev Med Liege,2010, 65(7-8) :450-452.
  • 9Brandao LG, Cavalheim BG, Junqueira CR. Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases. [J]. Clinics (Sao Paulo). 2009;64(9) :849-856.
  • 10Hazard JB, Hawk WA, Crite G. Medullary (solid) carcinoma of the thyroid; a elinicopathologic entity [ J ]. J Clin Endocrinol Metab.1959 .19(1) :152-161.

共引文献22

同被引文献11

  • 1张喜卿,张哉根,张同全,孙明祥,孙天玉.甲状腺髓样癌16例临床病理分析[J].诊断病理学杂志,2005,12(2):112-114. 被引量:6
  • 2Kebebew E,Ituarte PH,Siperstein AE,et al. Medullary thyroid car-cinoma: clinical characteristics, treatment, prognostic factors, and acomparison of staging systems [ J ]. Cancer, 2000,88 ( 5 ) : 1139-1148.
  • 3Hofstra RM,Landsvater RM,Ceccherini I,et al. A mutation in theRET proto-oncogene associated with multiple endocrine neoplasiatype 26 and sporadic medullary thyroid carcinoma [ J]. Nature,1994,367(6461) :375 -376.
  • 4Castellone MD, Santoro M. Dysregulated RET signaling in thyroidcancer[ J]. Endocrinol Metab Clin North Am, 2008,37 (2) : 363-374.
  • 5Yang KP,Castillo SG,Nguyen CV,et al. C-myc,N-myc,N-ras,andc-erb-B :lack of amplification or rearrangement in human medullarythyroid carcinoma and a derivative cell line[ J]. Anticancer Res,1990,10(1) :189 -92.
  • 6Yana I,Nakamura T,Shin E,et al. Inactivation of the p53 gene isnot required for tumorigenesis of medullary thyroid carcinoma orpheochromocytoma [ J ]. Jpn J Cancer Res, 1992, 83 ( 11 ):1113-1116.
  • 7Reubi JC,Chayvialle JA,Franc B,et al. Somatostatin receptors andsomatostatin content in medullary thyroid carcinomas[ J]. Lab In-vest, 1991,64(4) :567 -573.
  • 8胡淑阳,吴艺捷.甲状腺癌的肿瘤标志物研究进展[J].现代实用医学,2009,21(1):83-85. 被引量:6
  • 9楼建林,郭良,赵坚强.甲状腺髓样癌的分子病因学和靶向治疗进展[J].国际耳鼻咽喉头颈外科杂志,2013,37(4):230-233. 被引量:2
  • 10牛志强.30例甲状腺癌再次手术患者临床分析[J].肿瘤基础与临床,2014,27(4):353-354. 被引量:2

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部